Back to Authors

Kiernan, Matthew C

0000-0001-9054-026X

Mayo Clinic

Neuroscience Research Australia, University of New South Wales, Sydney, Australia.

Citations 5

Toward therapeutic trials in primary lateral sclerosis

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | July 6, 2025 | Volume: 26 | Issue: 7-8 | Pages: 623-630

10.1080/21678421.2025.2527123 | PMID 40618376

Preface: promoting research in PLS: current knowledge and future challenges

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | February 20, 2021 | Volume: 21 | Issue: sup1 | Pages: 1-2

10.1080/21678421.2020.1840795 | PMID 33602018

Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis

JAMA Neurology | November 23, 2020 | Volume: 78 | Issue: 2 | Pages: 186

10.1001/jamaneurol.2020.4300 | PMID 33226425

A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS

Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration | September 24, 2020 | Volume: 22 | Issue: 3-4 | Pages: 287-299

10.1080/21678421.2020.1822410 | PMID 32969758

Nerve Pathology Distinguishes Focal Motor Chronic Inflammatory Demyelinating Polyradiculoneuropathy From Multifocal Motor Neuropathy

Journal of Clinical Neuromuscular Disease | August 21, 2020 | Volume: 22 | Issue: 1 | Pages: 1-10

10.1097/cnd.0000000000000279 | PMID 32833719

Abstract Objectives: The objective of the study is to distinguish the mechanisms of disease for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and multifocal motor neuropathy (MMN), which we believe to be fundamentally different. However, distinguishing the mechanisms is more difficult when the presentation of CIDP is motor-predominant, focal, or asymmetric. Methods: We describe 3 focal, motor-predominant, representative cases that could be interpreted on clinical and/or electrophysiological grounds as either MMN or focal CIDP, and present pathological findings. Results: We highlight pathological differences in these cases, and provide an argument that CIDP and MMN are distinct entities with different pathophysiological mechanisms—chronic demyelination for CIDP, and an immune-mediated attack on paranodal motor axons for MMN. Conclusions: Based on clinical evaluation, electrophysiology, and nerve biopsy pathology, we can divide the conditions into inflammatory demyelinating neuropathy (focal CIDP) versus chronic axonal neuropathy (MMN). The divergent pathological findings provide further evidence that CIDP and MMN are fundamentally different disorders.